On Nov 9, 2021 Variant Bio closed a Series B round and raised $105,000,000 from General Catalyst, SoftBank Vision Fund, Vulcan Capital, featuring lead investors SoftBank Vision Fund.

About the company: Variant Bio is located at United States, North America.
“Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.”

Company website: http://www.variantbio.com